HC Wainwright keeps Fractyl Health at Buy, lifts target to $24 from $8
TradingView reports that HC Wainwright kept its Buy rating on Fractyl Health and raised the price target from $8 to $24, a 200% increase in the target price.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Analysts at HC Wainwright & Co. kept their Buy rating on Fractyl Health and lifted the price target to $24 from $8, a 200% increase. TradingView reported the update.
Based on the November 12 close of $0.81, the new target implies upside of about 2855.3%. Reference data was provided by Benzinga.
why it matters
Single-analyst target changes concern one company and rarely move the broader market. Investors typically weigh the reasoning behind such revisions, since a target is an analyst estimate rather than a recommendation to act.
tags
instruments
sources
- HC Wainwright & Co. maintains Fractyl Health at Buy, raises price target to $24 from $8 — TradingView, 13 November 2026 at 12:26 UTC
- HC Wainwright & Co. maintains Crescent Biopharma at Buy, raises price target to $40 from $36 — TradingView, 13 November 2026 at 12:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗